Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders

US9371324B2 · kind B2 · utility

Assignee

• INTRA-CELLULAR THERAPIES, INC. · US

Inventors

• Sharon Mates · New York, US
• Robert E. Davis · San Diego, US
• Lawrence P. Wennogle · Fryeburg, US
• Peng Li · New York, US
• John Charles Tomesch · Succasunna, US
• Qiang Zhang · Dalian, CN

Key dates

• Filing date: Feb 20, 2015
• Grant date: Jun 21, 2016
• Expiry date: Feb 20, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to particular substituted heterocycle fused gamma-carbolines, of Formula I as described herein, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems, such as diseases of the central nervous system.